Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 8

Ruxolitinib for the treatment of myelofibrosis: its clinical potential

Authors Ostojic A, Vrhovac R, Verstovsek S

Published Date March 2012 Volume 2012:8 Pages 95—103


Received 3 January 2012, Accepted 11 February 2012, Published 1 March 2012

Alen Ostojic1, Radovan Vrhovac1, Srdan Verstovsek2

1Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, Zagreb, Croatia; 2Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

Abstract: Ruxolitinib is an orally bioavailable, selective Janus kinase (JAK) 1 and 2 inhibitor approved for the treatment of myelofibrosis (MF), a bone marrow disease in which the JAK pathway is dysregulated, leading to impaired hematopoiesis and immune function. By inhibiting JAK1 and JAK2, ruxolitinib modulates cytokine-stimulated intracellular signaling. In a phase II clinical trial in patients with MF, ruxolitinib recipients exhibited durable reductions in spleen size, reductions in circulating pro-inflammatory cytokines, improvements in physical activity, weight gain, and alleviation of symptoms (including constitutional symptoms) in patients with and without JAK2 mutation. These findings were confirmed by two phase III clinical MF studies, in which a greater proportion of ruxolitinib recipients achieved a spleen volume reduction of ≥35% from baseline at week 24, compared with placebo in one study (41.9% versus 0.7%; P < 0.0001) and with best available therapy in the other (31.9% versus 0%; P < 0.0001). Alleviation of MF symptoms and improvements in quality of life were also significantly greater in ruxolitinib recipients. Overall survival of patients treated with ruxolitinib was significantly longer than of those receiving the placebo. Owing to risks of potentially serious adverse effects, eg, myelosuppression, ruxolitinib should be used under close physician supervision. Longer follow-up of the phase III MF studies is needed to reach firm conclusions regarding ruxolitinib’s capacity to modify the natural disease course.

Keywords: myelofibrosis, JAK2 inhibitor, ruxolitinib

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer

Chen XH, Li ZQ, Peng H, Jin SM, Fu HQ, Zhu TC, Weng XG

OncoTargets and Therapy 2013, 6:527-530

Published Date: 14 May 2013

Ruxolitinib as an emerging treatment in myelofibrosis

Emanuel RM, Geyer HL, Mesa RA

Blood and Lymphatic Cancer: Targets and Therapy 2013, 3:11-18

Published Date: 9 March 2013

Rituximab for managing acquired hemophilia A in a case of chronic neutrophilic leukemia with the JAK2 kinase V617F mutation

Imashuku S, Kudo N, Kubo K, Saigo K, Okuno N, Tohyama K

Journal of Blood Medicine 2012, 3:157-161

Published Date: 5 December 2012

Kinase inhibitors: a new class of antirheumatic drugs

Kyttaris VC

Drug Design, Development and Therapy 2012, 6:245-250

Published Date: 21 September 2012

Dual drug-loaded nanoparticles on self-integrated scaffold for controlled delivery

Bennet D, Marimuthu M, Kim S, An J

International Journal of Nanomedicine 2012, 7:3399-3419

Published Date: 16 July 2012

Use of a semiquantitative procalcitonin kit for evaluating severity and predicting mortality in patients with sepsis

Kenzaka T, Okayama M, Kuroki S, Fukui M, Yahata S, Hayashi H, Kitao A, Kajii E, Hashimoto M

International Journal of General Medicine 2012, 5:483-488

Published Date: 31 May 2012

Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson’s disease

Bossolasco P, Cova L, Levandis G, Diana V, Cerri S, Lambertenghi Deliliers G, Polli E, Silani V, Blandini F, Armentero MT

International Journal of Nanomedicine 2012, 7:435-447

Published Date: 31 January 2012

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009